Wall Street Associates’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Wall Street Associates’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-7,600	Closed	-$295K	–	234
2016 Q2	$295K	Hold	7,600	–	–	0.12%	179
2016 Q1	$211K	Hold	7,600	–	–	0.09%	215
2015 Q4	$409K	Sell	7,600 -198,057	-96%	-$9.99M	0.12%	230
2015 Q3	$8.23M	Sell	205,657 -153,200	-43%	-$5M	1.58%	4
2015 Q2	$11.5M	Sell	358,857 -6,500	-2%	-$165K	1.08%	14
2015 Q1	$8.72M	Sell	365,357 -5,400	-1%	-$121K	0.82%	27
2014 Q4	$6.54M	Sell	370,757 -1,200	-0.3%	-$18.7K	0.63%	58
2014 Q3	$5.1M	Sell	371,957 -21,300	-5%	-$320K	0.53%	73
2014 Q2	$6.63M	Sell	393,257 -1,100	-0.3%	-$18.2K	0.57%	63
2014 Q1	$7.17M	Buy	+394,357	New	+$7.12M	0.59%	62

Other funds holding ITCI

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCM

TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

HIM

Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Wall Street Associates's ITCI Position: Q3 2016 in Review

Wall Street Associates sold out of Intra-Cellular Therapies Inc. (ITCI) in Q3 2016, closing a stake of 7,600 shares — an estimated $295K sold.

Wall Street Associates first reported a position in ITCI in Q1 2014 and held it in 10 quarters. The position peaked at $11.5M in Q2 2015. 131 funds tracked by Wall St. Rank hold ITCI as of Q3 2016.

Wall Street Associates reported no remaining Intra-Cellular Therapies Inc. position as of Q3 2016 after selling out during the quarter.
Wall Street Associates sold 7,600 Intra-Cellular Therapies Inc. shares in Q3 2016, an estimated $295K.
Wall Street Associates first reported a position in Intra-Cellular Therapies Inc. in Q1 2014 and held it in 10 quarters.
Wall Street Associates's Intra-Cellular Therapies Inc. position peaked at $11.5M in Q2 2015.
131 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q3 2016.

Based on Wall Street Associates's 13F filing for Q3 2016, filed 14 Nov 2016.